Company to exhibit NovaMesh and next generation AVflo™ at MEDICA 2009
Lod, Israel and Düsseldorf, Germany, November 12, 2009 --- Nicast, developer of medical devices made of electrospun nanofabric, announced today it is readying to launch the NovaMesh intra-abdominal hernia mesh in the European market in Q1 2010, pending European regulatory approval. NovaMesh is the first intra-abdominal hernia mesh to utilize the special properties of electrospun nanofabric.
“In preclinical animal studies, NovaMesh has demonstrated excellent resistance to adhesions on the organ facing surface followed by regrowth of the peritoneum, strong tissue integration on the abdominal facing surface, and minimal mesh shrinkage,” stated Nicast CEO Benjamin Eliason. The findings of the preclinical study of the NovaMesh will be announced following the receipt of the final study report.
Nicast also announced today that it will exhibit the NovaMesh intra-abdominal hernia mesh and the next generation AVflo vascular access graft at MEDICA 2009, November 18-21 in Düsseldorf, Germany. Nicast’s booth is located in Hall 5 at booth number N05.
AVflo is a self-sealing vascular access graft that enables unobstructed blood flow, allows for dialysis within 24-48 hours after implantation and self-seals within less than five minutes following withdrawal of the dialysis needles. The AVflo received CE certification in October 2008. The Company plans to introduce the improved version of the AVflo vascular access graft to the European market in the first quarter of 2010.
“Nicast is strengthening its production capabilities in order to meet the anticipated market demand for both the NovaMesh and the improved AVflo. We continue to actively build our distribution base noting the high enthusiasm emerging from our discussions with distributors throughout Europe. We are looking forward to speaking with additional potential partners at Medica,” said Mr. Eliason.
About Nicast Ltd.
Nicast Ltd. is a pioneer in the development of superior implantable medical devices made of electrospun polymer nanofabrics for a wide range of applications. The company is currently focused on the development and marketing of the AVflo vascular access graft and the NovaMesh intra-abdominal hernia mesh, which address a combined global market of $0.7 billion to $1 billion. Headquartered in Lod, Israel, Nicast has six patents in the U.S., ten patents outside of the U.S. and 16 additional patents pending. For more information please visit the company’s web site at www.nicast.com. To schedule an interview or an appointment with CEO Mr. Benjamin Eliason, please contact Marjie Hadad, media liaison, at +972-54-536-5220 or at firstname.lastname@example.org.